Captor Therapeutics Spolka Akcyjna (WSE:CTX)

Market Cap	431.24M +97.2%
Revenue (ttm)	7.57M -60.9%
Net Income	-40.71M
EPS	-7.69
Shares Out	5.53M
PE Ratio	n/a
Forward PE	180.35
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,138
Average Volume	8,478
Open	78.00
Previous Close	78.00
Day's Range	77.80 - 82.20
52-Week Range	31.20 - 86.00
Beta	0.71
RSI	53.09
Earnings Date	Apr 2, 2026

About WSE:CTX

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. Its products in various stages of development include CT-03, which has completed the Phase 1 clinical trials for the treatment of non-small cell lung cancer, triple-negative breast cancer, as well as cancers of the...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 91
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: CTX

Financial Performance

In 2024, WSE:CTX's revenue was 15.83 million, an increase of 19.88% compared to the previous year's 13.20 million. Losses were -38.43 million, -45.56% less than in 2023.